Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US clears Amgen's Nplate with restricted distribution scheme

This article was originally published in Scrip

Executive Summary

The US FDAhas required a restricted distribution programme and mandatory postmarketing studies for Amgen's novel thrombopoietin receptor agonist Nplate (romiplostim). The agency approved Nplate on August 22nd for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000322

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel